Ajuts a la recerca

Macrovascular Complications of Diabetes

Organisme

European Foundation for the Study of Diabetes (EFSD)- AstraZeneca

Objecte

EFSD has established this Clinical Diabetes Research Programme in Macrovascular Complications of Diabetes to stimulate and acclerate European clinical research, and encourage projects aimed at advancing current knowledge in this field.

To achieve the goals and objectives of this Programme, EFSD invite applications by issuing this "Request for Applications" (RFA), which indicates joint funding as well as areas of research emphasis.

Cardiovascular disease is the leading cause of morbidity and mortality in people with type 2 diabetes, the risk of CV disease being 2 to 3 times higher in people with diabetes compared to those without diabetes. Aggressive control of CV risk factors reduces the risk of cardiovascular events, and there is conclusive evidence that improving glycaemic control significantly reduces the risk of developing diabetic microvascular complications. There is also a need to better understand the effects of antidiabetic medications (i.e. GLP-1 RA, DPPlV inhibitors, SGLT2 inhibitors) on the cardiovascular system and their actions on cardiovascular disease in type 2 diabetes.

Termini oficial

Deadline for submission of applications: 1 November 2014

Termini IISPV

IISPV's deadline:  October 10, 2014 (europa@iispv.cat) Full proposal: IISPV's deadline: October 27, 2014

Pujar